A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: Part II

Psychosomatics

Volumn 49, Issue 4, 2008, Pages 347-361

  De Leon, Jose ^a,b,c,d   Sandson, Neil B ^e,f,g   Cozza, Kelly L ^h,i  

^a EASTERN STATE HOSPITAL   (United States)

^b Eastern State Hospital   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF GRANADA   (Spain)

^e VISN 5 MIRECC   (United States)

^f SHEPPARD PRATT HEALTH SYSTEM   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h WALTER REED ARMY MEDICAL CENTER   (United States)

ⁱ UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; CLOZAPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DELAVIRDINE; DILTIAZEM; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EFAVIRENZ; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; GLYCOPROTEIN P; HALOPERIDOL; KETOCONAZOLE; NEUROLEPTIC AGENT; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; PROTEINASE INHIBITOR; RIFAMPICIN; RISPERIDONE; SERTRALINE;

AGING; ALZHEIMER DISEASE; CLINICAL TRIAL; DEMENTIA; DISEASE ASSOCIATION; DOPAMINE METABOLISM; DOPAMINE RECEPTOR BLOCKING; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENVIRONMENTAL FACTOR; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; MANIA; MENTAL DEFICIENCY; MONOTHERAPY; ORGANIC BRAIN SYNDROME; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PHARMACOGENETICS; POLYPHARMACY; PRACTICE GUIDELINE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

EID: 46149124547     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.49.4.347     Document Type: Article

References (201)

1. McKusick VA: The anatomy of the human genome: a neo-vesalian basis for medicine in the 21st century. JAMA 2001; 286:2289-2295
2. Redon R, Ishikawa S, Fitch KR, et al: Global variation in copy number in the human genome. Nature 2006; 444:444-454
3. Fodor SP: Massively parallel genomics. Science 1997; 277:393-395
4. Science: New research horizons. Science 1997; 278:2039
5. Lertola J: Deciphering the code and what might come from it. Time 1999; Nov 8:68-69
6. Collins FS, McKusick VA: Implications of the human genome project for medical science. JAMA 2001; 285:540-544
7. Kirchheiner J, Nickchen K, Bauer M, et al: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9:442-473
8. de Leon J, Armstrong SC, Cozza KL: Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006; 47:75-85
9. de Leon J: The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultra-rapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19. J Clin Psychopharmacol 2007; 27:241-245
10. Preskorn SH; A message from the Titanic. J Pract Psychiatry Be-hav Health 1998; 4:236-242
11. Arranz MJ, de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of the last decade of research. Mol Psychiatry 2007; 12:707-747
12. Martin K, Begaud B, Verdoux H, et al: Patterns of risperidone prescription: a utilization study in southwest France. Acta Psychiatr Scand 2004; 109:202-206
13. de Leon J, Susce MT, Pan RM, et al: CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66:15-27
14. Williams R: Optimal dosing with risperidone: updated recommendations. J Clin Psychiatry 2001; 62:282-289
15. Olfson M, Blanco C, Liu L, et al: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63:679-685
16. Buckley PF: Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001; 50:912-924
17. Shekelle P, Maglione M, Bagley S, et al: Comparative effectiveness of off-label use of atypical antipsychotics, in Comparative Effectiveness Review No. 6. Rockville, MD, Agency for Healthcare Research and Quality, 2007
18. Reist C, Mintz J, Albers LJ, et al: Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol 2007; 27:46-51
19. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
20. Chouinard G, Jones B, Remington G, et al: A Canadian multicenter, placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychopharmacol 1997; 17:194-201
21. Peuskens J, Risperidone Study Group: Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166:712-726
22. Tauscher J, Kapur S: Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 2001; 15:671-678
23. Carter CS, Mulsant BH, Sweet RA, et al: Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Psychopharmacol Bull 1995; 31:719-725
24. Lemmens P, Brecher M, Van Baelen B: A combined analysis of double-blind studies of risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999; 99:160-170
25. Simpson GM, Lindenmayer JP: Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997; 17:194-201
26. Schillevoort I, de Boer A, Herings RM, et al: Antipsychotic-induced extrapyramidal syndromes: risperidone compared with low-and high-potency conventional antipsychotic drugs. Eur J Clin Pharmacol 2001; 57:327-331
27. Kinon BJ, Ahl J, Stauffer VL, Hill AL, et al: Dose response and atypical antipsychotics in schizophrenia. CNS Drugs 2004; 18:597-616
28. Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev 2004; 5:645-656
29. Kraemer HC, Kupfer DJ: Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2005; 59:990-996
30. de Leon J, Diaz FJ: Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus, and hyperlipidemia) may be a reasonable strategy. Schizophr Res 2007; 96:185-197
31. Richelson E: Preclinical pharmacology of neuroleptics: focus on new-generation compounds. J Clin Psychiatry 1996; 57(suppl 11):4-11
32. 2 dopamine receptor missense variants. Pharmacogenetics 1999; 9:17-21
33. Cai WM, Nikoloff DM, Pan RM, et al: CYP2D6 genetic variations in healthy adults in psychiatric African American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J 2006; 6:343-350
34. 3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005; 25:448-456
35. 2A receptors and clozapine response. Schizophr Res 1998; 32:93-99
36. Arranz MJ, Munro J, Birkett J, et al: Pharmacogenetic prediction of clozapine response. Lancet 2000; 355:1615-1616
37. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors: focus on newer-generation compounds. Life Sci 2000; 68:29-39
38. Schotte A, Janssen PF, Gommeren W, et al: Risperidone compared with new and reference antipsychotic drugs: in-vitro and in-vivo receptor binding. Psychopharmacology 1996; 124:57-73
39. Seeman P, Lee T, Chau-Wong M, et al: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261:717-719
40. 4. Neuropsychopharmacology 1992; 7:261-284
41. 2 receptor explain the action of atypical antipsychotics? Am J Psychiatry 2001; 158:360-369
42. Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotics. Psychopharmacol Bull 1989; 25:390-392
43. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998; 3:123-134
44. Shayegan DK, Stahl SM: Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 2004; 9(10 suppl 11):6-14
45. Fernandez HH, Trieschmann ME, Friedman JH: Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003; 26:643-659
46. Katz IR: Optimizing atypical antipsychotic treatment strategies in the elderly. J Am Geriatr Soc 2004; 52(12 suppl):S272-S277
47. Stevens J: An anatomy of schizophrenia? Arch Gen Psychiatry 1973; 29:177-189
48. Abi-Dargham A, Laruelle M: Mechanism of action of second-generation antipsychotic drugs in schizophrenia: insight for brain-imaging studies. Eur Psychiatry 2005; 20:15-27
49. Kapur S, Agid O, Mizrahi R, et al: How antipsychotics work: from receptors to reality. Neuro Rx 2006; 3:10-21
50. Finkel S: Pharmacology of antipsychotics in the elderly: a focus on atypicals. J Am Geriatr Soc 2004; 52(12 suppl):S258-S265
51. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 2001; 90:231-259
52. 3 dopamine receptor affinity of dopaminergic compounds in rat brain. Life Sci 1998; 62:1825-1831
53. 3 receptor occupancy by risperidone: a[123I]-epidepride SPECT study. J Clin Psychopharmacol 2003; 23:5-14
54. 3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatrie disorders. Curr Pharm Des 2003; 9:643-671
55. Malek-Ahmadi P, Chapel JL: Tolerance to phenothiazines in schizophrenic patients. Gen Pharmacol 1976; 7:377-379
56. Casey DE: The relationship of pharmacology to side effects. J Clin Psychiatry 1997; 58(suppl 10):55-62
57. Agarwal V: Urinary incontinence with risperidone (letter). J Clin Psychiatry 2000; 61:219
58. Madhusoodanan S, Brenner R. Agarwal V: Risperidone-induced ejaculatory and urinary dysfunction (letter). J Clin Psychiatry 1996; 57:549-550
59. Ruggieri MR, Braverman AS, Pontari MA: Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 2005; 174:1743-1748
60. Vera PL, Miranda-Sousa A, Nadelhaft I: Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats. BMC Pharmacol 2001; 1:4
61. Nakonezny PA, Byerly MJ, Rush AJ: The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized, double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther 2007; 33:203-216
62. Bolonna AA, Arranz MJ, Munro J, et al: No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett 2000; 280:65-68
63. Hsu JW, Wang YC, Lin CC, et al: No evidence for association of alphala adrenoceptor gene polymorphism and clozapine-induced urinary incontinence. Neuropsychobiology 2000; 42:62-65
64. 2a-adrenoreceptor gene with schizophrenia and clozapine response. Schizophr Res 2001; 49:53-58
65. Remeron package insert : West Orange, NJ, Organon, 2002
66. 2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug response. Prog Neuro-Psychopharmacol Biol Psychiatry 2005; 29:1021-1028
67. 2C serotonin receptors. Nature 1995; 374:542-546
68. Wirshing DA, Wirshing WC, Kysar L, et al: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60:358-363
69. Matsui-Sakata A, Ohtani H, Sawada Y: Receptor occupancy-based analysis of the contributions of various receptors to antipsychotic-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005; 20:368-378
70. 2C receptor gene polymorphism. Lancet 2002; 359:2086-2087
71. Lane HY, Liu YC, Huang CL, et al: Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006; 26:128-134
72. Duinkerke SJ, Botter PA, Jansen AA, et al: Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia: a placebo-controlled, double-blind trial. Br J Psychiatry 1993; 163:451-455
73. Strauss WH, Klieser E: Psychotropic effects of ritanserin, a selective S2 antagonist: an open study. Eur Neuropsychopharmacol 1991; 1:101-105
74. 2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990; 13:500-506
75. Ceulemans DL, Hoppenbrouwers ML, Gelders YG, et al: The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind, placebo-controlled study versus lorazepam. Pharmacopsychiatry 1985; 18:303-305
76. 2 receptor antagonism in dysthymic disorder: a double-blind, placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991; 83:244-248
77. Wiesbeck GA, Weijers HG, Chick J, et al: Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled, double-blind, international multicenter trial: Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 1999; 23:230-235
78. 1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 2007; 104:3456-3459
79. Hartfield AW, Moore NA, Clifton PG: Serotonergic and histaminergic mechanisms involved in Intralipid drinking? Pharmacol Biochem Behav 2003; 76:251-258
80. 3 receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics. Naunyn Schmiedebergs Arch Pharmacol 1996; 353:290-294
81. 1 antihistamines. J Clin Psychopharmacol 2002; 22:511-515
82. Hong CJ, Lin CH, Yu YW, et al: Genetic variant of the histamine, receptor (glu349asp) and body weight change during clozapine treatment. Psychiatr Genet 2002; 12:169-171
83. Mancama D, Arranz MJ, Munro J, et al: Investigation of promoter variants of the histamine-1 and -2 receptors in schizophrenia and clozapine response. Neurosci Lett 2002; 333:207-211
84. Newcomer JW, Haupt DW: The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51:480-491
85. Henderson DC: Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002; 16:77-89
86. Newcomer JW: Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004; 65(suppl 18):36-46
87. Wang C, Zhang Z, Sun J, et al: Serum-free fatty acids and glucose metabolism: insulin resistance in schizophrenia with chronic antipsychotics. Biol Psychiatry 2006; 60:1309-1313
88. Meyer JM, Koro CE: The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70:1-17
89. Gill SS, Rochon PA, Hermann N, et al: Atypical antipsychotic drugs and risk of ischemic stroke: population-based retrospective cohort study. BMJ 2005; 330:445-450
90. Harrigan EP, Miceli JJ, Anziano R, et al: A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24:62-69
91. Buckley NA, Sanders P: Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000; 23:215-228
92. Drolet B, Yang T, Daleau P, et al: Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol 2003; 41:934-937
93. Gupta S, Masand P, Kothari AJ: Cardiovascular side effects of novel antipsychotics. CNS Spectrums 2001; 6:912-918
94. Capel MM, Colbridge MG, Henry JA: Overdose profile of new antipsychotic agents. Int J Neuropsychopharmacol 2000; 3:51-54
95. Wilton LV, Heeley EL, Pickering RM, et al: Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001; 15:120-126
96. Miller AL, Hall CS, Buchanan RW, et al: The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2003 Update. J Clin Psychiatry 2004; 65:500-508
97. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision). Am J Psychiatry 2002; 159(suppl 4):1-50
98. Preskorn SH, Lacey RL: Polypharmacy: when is it rational? Journal of Practical Psychiatry and Behavioral Health 1995; 1:2:92-98
99. Kingsbury SJ, Yi D, Simpson GM: Rational and irrational polypharmacy. Psychiatr Serv 2001; 52:1033-1036
100. Haase HJ, Janssen PAJ: The Action of Neuroleptic Drugs. Chicago, IL, Yearbook Medical Publishers, 1985
101. Simpson GM, Krakov L, Mattke D, et al: A controlled comparison of the treatment of schizophrenic patients when treated according to the neurologic threshold or by clinical judgment. Acta Psychiatr Scand 1970; 212(suppl):38-43
102. McEvoy JP, Stiller RL, Farr R: Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study. J Clin Psychopharmacol 1986; 6:133-138
103. McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48:739-745
104. Woods SW: Chlorpromazine-equivalent doses for newer atypical antipsychotics. J Clin Psychiatry 2003; 64:663-667
105. Schooler N, Rabinowitz J, Davidson M, et al: Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162:947-953
106. Remington G: Rational pharmacotherapy in early psychosis. Br J Psychiatry 2005; 48(suppl):S77-S84
107. Kurachi M, Shibata R, Murata M, et al: Parallel development of dopamine metabolism tolerance in the rat prefrontal cortex, caudate-putamen, and amygdala following haloperidol decanoate administration. Biol Psychiatry 1995; 37:487-490
108. Samaha AN, Seeman P, Stewart J, et al: "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007; 27:2979-2986
109. Reeves S, Bench C, Howard R: Ageing and the nigrostriatal dopaminergic system. Int J Geriatr Psychiatry 2002; 17:359-370
110. Stark AK, Pakkenberg B: Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Res 2004; 318:81-92
111. DeVane CL, Mintzer J: Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update. Psychopharmacol Bull 2003; 37:116-132
112. Palmer AM, DeKosky ST: Monoamine neurons in aging and Alzheimer's disease. J Neural Transm Gen Sect 1993; 91:135-159
113. Lester J, Otero-Siliceo E: Parkinson's disease and genetics. Neurologist 2006; 12:240-244
114. Chade AR, Kasten M, Tanner CM: Nongenetic causes of Parkinson's disease. J Neural Transm suppl 2006; 70:147-151
115. Fung HC, Scholz S, Matarin M, et al: Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first-stage analysis and public release of data. Lancet Neurol 2006; 5:911-916
116. Deng H, Le W, Huang M, et al: Genetic analysis of the LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neurosci Lett 2007; 419:104-107
117. Koller WC: When does Parkinson's disease begin? Neurology 1992; 42(suppl 4):27-31
118. Braak H, Ghebremedhin E, Rüb U, et al: Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318:121-134
119. Mena MA, de Yebenes JG: Drug-induced parkinsonism. Expert Opin Drug Saf 2006; 5:759-771
120. Scherzer CR, Eklund AC, Morse LJ, et al: Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A 2007; 104:955-960
121. Berg D: Transcranial sonography in the early and differential diagnosis of Parkinson's disease. J Neural Transm Suppl 2006; 70:249-254
122. Reiter PJ: Extrapyramidal motor-disturbances in dementia praecox. Acta Psychiatr Neurol 1926; 1:287-310
123. Caligiuri MP, Lohr JB, Jeste DV: Parkinsonism in neuroleptic-naive schizophrenic patients. Am J Psychiatry 1993; 150:1343-1348
124. Chatterjee A, Chakos M, Koreen A, et al: Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenia patients. Am J Psychiatry 1995; 152:1724-1729
125. Peralta V, Cuesta MJ, Martinez-Larrea A, et al: Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry 2000; 157:1461-1466
126. Honer WG, Kopala LC, Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic-exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol 2005; 19:277-285
127. De Erausquin GA: Neurodevelopment and schizophrenia. Vertex 2002; 13:189-197
128. Kopala LC, Good KP, Honer WG: Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997; 17:308-313
129. Aman MG, Madrid A: Atypical antipsychotics in persons with developmental disabilities. Ment Retard Dev Disabil Res Rev 1999; 5:253-263
130. Aman MG, Gharabawi GM; Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients with Mental Retardation and Developmental Disabilities: Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. J Clin Psychiatry 2004; 65:1197-1210
131. McCracken JT, McGough J, Shah B: Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347:314-321
132. Janssen: Risperdal (Risperidone). Package insert (revised December 2006), Titusville, NJ, Janssen, 2006
133. West L, Waldrop J: Risperidone use in the treatment of behavioral symptoms in children with autism. Pediatr Nurs 2006; 32:545-549
134. Findling RL, McNamara NK: Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 2004; 65(suppl 6):30-44
135. Cheng-Shannon J, McGough JJ, Pataki C, et al: Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14:372-394
136. McConville BJ, Sorter MT: Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 2004; 65(suppl 6):20-29
137. Simpson GM, Pi EH, Sramek JJ: Neuroleptics and antipsychotics, in Meyler's Side Effects of Drugs, 11th Edition. Edited by Dukes MNG. Amsterdam, The Netherlands, Elsevier, 1988
138. de Leon J, Susce MT, Murray-Carmichael E: The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diag Ther 2006; 10:135-151
139. Armstrong SC, Cozza KL, Sandson NB: Six patterns of drug-drug interactions. Psychosomatics 2003; 44:255-258
140. Alan DA, Sharma RP: Cytochrome enzyme genotype and the prediction of therapeutic response to psychotropics. Psychiatr Ann 2001; 31:715-722
141. Yasui-Fururoki N, Mihara K, Kondo T, et al: Effect of CYP2D6 genotypes on plasma concentration of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol 2003; 43:122-127
142. CYP450 website:http://www.cypalleles.ki.se
143. Chou WH, Yan FX, Robbins-Weilert DK, et al: Comparison of two CYP2D6 genotyping methods and assessments of genotype-phenotype relationships. Clin Chemistry 2003; 49:542-551
144. de Leon J, Susce MT, Pan RM, et al: A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007; 40:93-102
145. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans, and their descendants. Pharmacogenomics 2002; 3:229-243
146. Ingelman-Sundberg M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects, and functionary diversity. Pharmacogenomics J 2005; 5:6-13
147. de Leon J: The AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 2006; 6:277-286
148. Gaedigk A, Bradford LD, Marcucci KA, et al: Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002; 72:76-89
149. Gaedigk A, Bradford LD, Alander SW, et al: CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor-metabolizer status. Drug Metab Dispos 2006; 34:563-569
150. Wennerholm A, Dandara C, Sayi J, et al: The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002; 71:77-88
151. Megens AA, Awouters FH, Schotte A, et al: Survey on pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 1994; 114: 9-23
152. Heykants J, Huang ML, Mannens G, et al: The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994; 55(suppl 5):13-17
153. Huang ML, Van Peer A, Woestenborghs R, et al: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54:257-268
154. Bork J, Rogers T, Wedlund P, et al: A pilot study of risperidone metabolism: the role of cytochrome P450 2D6 and 3A. J Clin Psychiatry 1999; 60:469-476
155. Albrecht A, Morena PG, Baumann P, et al: High dose of depot risperidone in a nonresponder schizophrenic patient. J Clin Psychopharm 2004; 24:673-674
156. Guzey C, Aamo T, Spigset O: Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultra-rapid metabolizer (letter). J Clin Psychiatry 2000; 61:600-601
157. Madan A, Graham RA, Carroll KM, et al: Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003; 31:421-431
158. de Leon J, Bork JA: Risperidone and the cytochrome P4503A (letter). J Clin Psychiatry 1997; 58:450
159. Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999; 359:147-151
160. Yasui-Furukori N, Hidestrand M, Spina E, et al: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001; 29:1263-1268
161. Westlind-Johnsson A, Hermann R, Huennemeyer A, et al: Identification and characterization of CYP3A4*20, a novel rare CYP3A allele without functional activity. Clin Pharmacol Ther 2006; 79:339-349
162. Wilkinson GR: Genetic variability in cytochrome P450 3A5 and in-vivo cytochrome P450 3A activity: some answers, but still questions. Clin Pharmacol Ther 2004; 76:91-103
163. Kuehl P, Zhang J, Lin Y, et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391
164. de Leon J, Armstrong SC, Cozza KL: The dosing of atypical antipsychotics. Psychosomatics 2005; 46:262-273
165. Yatham LN, Grossman F, Augustyns I, et al: Mood stabilisers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomised, controlled trial. Br J Psychiatry 2003; 182:141-147
166. Barnhill J, Susce MT, Diaz FJ, et al: Risperidone half-life in a patient taking paroxetine: a case report. Pharmacopsychiatry 2005; 38:223-225
167. van Beijsterveldt LEC, Geerts RJF, Leysen JE, et al: Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperdone in the rat. Psychopharmacology 1994; 114:53-62
168. Aravagiri M, Yuwiler A, Marder SR: Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology 1998; 139:356-363
169. Wang JS, Ruan Y, Taylor RM, et al: The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by p-glycoprotein. Int J Neuropsychopharmacol 2004; 7:415-419
170. Endres CJ, Hsiao P, Chung FS, et al: The role of transporters in drug interactions. Eur J Pharm Sci 2006; 27:501-517
171. Sasongko L, Link JM, Muzi M, et al: Imaging P-glycoprotein transport activity at the human blood-barrier with positron emission tomography. Clin Pharmacol Ther 2005; 77:503-514
172. Nakagami T, Yasui-Furukori N, Saito M, et al: Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: invivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 2005; 78:43-51
173. Bergley DJ: ABC transporter and the blood-brain barrier. Curr Pharm Design 2004; 10:1295-1312
174. Loscher W, Potschka H: Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2:86-98
175. Boulton DW, DeVane CL, Liston HL, et al: In-vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71:163-169
176. El Ela AA, Hartter S, Schmitt U, et al: Identification of p-glycoprotein substrates and inhibitors among psychoactive compounds: implications for pharmacokinetics of selected substrates. J Pharmacy Pharmacol 2004; 56:967-975
177. Uhr M, Grauer MT, Holsboer F: Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) p-glycoprotein gene disruption. Biol Psychiatry 2003; 54:840-846
178. Cousein E, Barthelemy C, Poullain S, et al: P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using in-vitro Caco-2/TC7 model and in-vivo model. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:878-886
179. Cascorbi I, Gerloff T, Johne A, et al: Frequency of single-nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-174
180. Roberts RL, Joyce PR, Mulder RT, et al: A common p-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2:191-196
181. Hoffmeyer S, Burk O, von Richter O, et al: Functional polymorphism of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97:3473-3478
182. Schwab M, Eichelbaum M, Fromm MF: Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003; 43:285-307
183. Ieiri I, Takane H, Otsubo K: The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004; 43:553-576
184. Marzolini C, Paus E, Buclin T, et al: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33
185. Woodahl EL, Ho RJ: The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 2004; 5:11-19
186. Zheng H, Schuetz E, Zeevi A, et al: Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes. J Clin Pharmacol 2005; 45:404-410
187. Yasui-Fururoki N, Mihara K, Takahata T, et al: Effect of various factors on steady-state plasma concentration of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 2004; 57:569-575
188. Lamba J, Strom S, Venkataramanan R, et al: MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 2006; 79:325-338
189. Kapur S, Langlois X, Vinken P, et al: The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002; 302:1129-1134
190. Wittkowski W: Tanycytes and pituicytes: morphological and functional aspects of neuroglial interaction. Microsc Res Tech 1998; 41:29-42
191. Tachibana O, Yamashima T, Yamashita J, et al. Immunohistochemical expression of human chorionic gonadotropin and P-glycoprotein in human pituitary glands and craniopharyngiomas. J Neurosurg 1994; 80:79-84
192. Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005; 162:1010-1012
193. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006; 2:529-532
194. Troost PW, Lahuis BE, Hermans MH, et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 2007; 27:52-57
195. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal, and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology 1995; 122:223-229
196. Mannens G, Haung M, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21:1134-1141
197. Balant-Gorgia AE, Gex-Fabry M, Genet C, et al: Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monit 1999; 21:105-115
198. Aichhorn W, Weiss U, Marksteiner J, et al: Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol 2005; 19:395-401
199. Gareri P, De Fazio P, De Fazio S, et al: Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging 2006; 23:937-956
200. Cotreau MM, von Moltke LL, Greenblatt DJ: The influence of age and sex on the clearance of cytochrome P450 3A substrate. Clin Pharmacokinet 2005; 44:33-60
201. Anderson CB, True JE, Ereshefsky L, et al: Risperidone dose, plasma levels, and response, in New Research Program and Abstracts, presented at Annual Meeting, American Psychiatric Assoc, San Francisco, CA, May 1993 (NR 217; p 113)